## The Guam Board of Examiners for Pharmacy

## Regular Board Meeting

Thursday, March 20, 2025 at 7:30 AM

Join Zoom Meeting

https://us06web.zoom.us/j/81046813565?pwd=1NOAjOSPJwRvRIM8itxeLEpNPfDzOQ.1

Meeting ID: 810 4681 3565 Passcode: 056976 MINUTES

Item		Discussion		Responsible Party	Reporting Timeframe	Status
I	Call to Order	Meeting Chaired by: J. Sana		Chair	0745	Call to Order
		A. Roll Call:	Other Attendees	Chair	0745	Quorum Established
		GBEP Members	<u>Present at HPLO</u> :			Established
		<u>Present at HPLO Conference</u> :	Baltazar (Tre) Hattori III, HPLO			
		☐Melissa Gabriel, Chairperson	<u>Virtual Attendance:</u>			
		⊠Art Mariano, Treasurer	Breanna Sablan, HPLO			
		⊠Jed Sana, Vice-Chair	Joaquin Blaz, DPHSS			
		⊠Angelina Eustaquio, Secretary				
		B. Confirmation of Public Notice:				Confirmed,
		Guam Daily Post: 03/13/25 and 03/18/25				
II	Approval of Agenda	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.		GBEP	0745	Unanimously Adopted Agenda
III	Review and	Draft Minutes dated 02/20/2025		GBEP	0747	Unanimously
	Approval of Minutes	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.				Approved
IV	HPLO	B. Sablan reminded the board about the disclosure of conflict of interest with the Guam Election		B. Sablan	0748	Noted
	Administrator's	Commission. She mentioned that the discretization is due by right 22, 2025, and can be submitted that the				
	Report	email or in person to the Guam Election Commission.		an En	05.40	
V	GBEP	A. GBEP-CO-16-01 – On-going		GBEP	0749	In-Progress,
	Complaints	B. Hattori provided an update on ongoing communication with the attorney, David Rivera, who has				
		reached out with a few questions. It was noted that the attorney is actively working on the matter and				
		expects to have a report in the coming weeks. He indicated that the situation is still ongoing and expressed hope for updates at the next meeting.				
		B. GBEP-CO-24-02 – On-going				In-Progress
VI	Old Business	A. PHARMACIES/FACILITIES/WHOLESALERS:		GBEP	0749	
, ,	Old Business	1. ZimVie US Corp LLC				Tabled
		J. Sana provided an update on this application, which had been tabled during the last meeting for				Clarifications and More
		further information. He highlighted ongoing uncertainties concerning over-the-counter				Information is
		medications and other manufactured items, apart from dental implants. An email update clarified				Necessary to Proceed.

Item		Discussion	Responsible Party	Reporting Timeframe	Status
		that the company does not currently offer any OTC or pharmacological products and that their focus is solely on dental products and biologics for dental applications. A. Eustaquio noted that the company had not yet received a certificate for the application. J. Sana mentioned that after reviewing the company's website, he found no relevant information that would fall under the Board's jurisdiction, particularly in relation to pharmacy. There was some confusion about the term "biologics," and A. Mariano indicated a need for further clarification regarding whether the company should apply as a distributor or if they intend to directly distribute to practitioners or other entities. J. Sana also suggested that more information was needed to determine if the company would need to apply as a manufacturer or could operate without a license, depending on their response.  Tabled Until the Next Meeting: J. Sana.			
VII	New Business	A. PHARMACIST BY ENDORSEMENT	GBEP	0753	
		<ol> <li>Ebenezer Aniagyei         Motion to Conditionally Approve Pending MPJE: A. Mariano; 2<sup>nd</sup>: A. Eustaquio.</li> <li>Charles R. Konkus</li> </ol>			Unanimously Conditionally Approved Unanimously Approved
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio. <b>B. PHARMACY TECHNICIANS:</b>		GBEP		**
		1. Roden Persam DB Cortez  Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
		2. Hartkaifa L. Billote Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
		J. Sana reported that the applicant has completed the required hours and certification, and the application is now complete with the necessary letters of recommendation. Only two board signatures are currently on the application, and they are awaiting a third, specifically from M. Gabriel, before finalizing the process. The applicant received training at Mega Drug.			Unanimously Conditionally Approved
	Motion to Conditionally Approve Pending Third Board Signature: A. Eustaquio; 2 <sup>nd</sup> : J. Sana.  C. PHARMACIES/FACILITIES/WHOLESALERS:		GBEP	-	
		1. McKesson Medical-Surgical Inc. (Houston, TX)  Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
		2. McKesson Medical-Surgical Inc. (Bartlett, IL)  Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
		3. McKesson Medical-Surgical Inc. (Roseville, CA)  Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
		<b>4.</b> McKesson Medical-Surgical Inc. (Clear Brook, VA)  Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
		5. McKesson Medical-Surgical Inc. (Commerce City, CO)  Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
		6. McKesson Medical-Surgical Inc. (Grapevine, TX)			Unanimously

Item	Discussion	Responsible Party	Reporting Timeframe	Status
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	7. McKesson Medical-Surgical Inc. (Kent, WA)			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	8. Curexa – West, LLC dba Curexa			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	9. Henry Schein, Inc. (Fort Worth, TX)			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	10. Henry Schein, Inc. (Sparks, NV)			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	11. Henry Schein, Inc. (Denver, PA)			Unanimously
	J. Sana mentioned that if the applicant has a local inspection report, they can submit it as well.			Conditionally Approved
	Motion to Conditionally Approve Pending Update on NABP Inspection: A. Eustaquio; 2 <sup>nd</sup> : A.			Арріочец
	Mariano.			
	12. Henry Schein, Inc. (Indianapolis, IN)			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	13. Henry Schein, Inc. (Bastian, VA)			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	14. Henry Schein, Inc. (Jacksonville, FL)			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	15. The Hibbert Company dba The Hibbert Group (New Castle, DE)			Unanimously
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			Approved
	16. The Hibbert Company dba The Hibbert Group (Trenton, NJ)			Unanimously
	J. Sana noted that although the applicant is not licensed by New Jersey, they are inspected by the			Approved
	FDA. The inspection included in the application was conducted by an FDA investigator, and no			
	Form 483 was issued, indicating that no findings were identified during the inspection.			
	Motion to Approve: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.			
	17. IMPRIMIS NJOF, LLC			Tabled
	J. Sana reported that the application in question has not yet received any board signatures. The			Pending More Information
	applicant is a manufacturer of ophthalmic products and has shared an ongoing investigation by			on Citations
	the California State Board of Pharmacy, along with observations suggesting non-compliance with			that were Received.
	some of the Board's regulations. Additionally, the applicant has been seeking an FDA Form 483,			Received.
	which would indicate any findings from the FDA. He noted that the applicant is licensed in			
	multiple states, including holding an active New Jersey registration as a manufacturer. He			
	recommended waiting for the results of the California Board of Pharmacy investigation or any			
	updates from the FDA, while also gathering more information from the applicant. A. Mariano			
	agreed in gathering more information and awaiting the findings from the FDA, or until all			
	necessary conditions were met, before proceeding. The board decided to table the matter for the			
	time being, pending further information related to the citations that were found and if satisfactory			
	evidence is provided showing that steps are being taken to address and correct the cited issues.			

Item		Discussion	Responsible Party	Reporting Timeframe	Status
		<b>18. MAH Pharmacy, LLC dba CHD Pharmacy</b> <i>Motion to Approve: A. Mariano;</i> 2 <sup>nd</sup> : A. Eustaquio.			Unanimously Approved
VIII	Next Board Meeting	<b>A.</b> The next Guam Board of Examiners for Pharmacy Regular Session Meeting is scheduled for April 17, 2025 at 7:30 a.m.	GBEP	0822	Set Date
IX	Adjournment	Motion to Adjourn: A. Mariano; 2 <sup>nd</sup> : A. Eustaquio.	GBEP	0822	Adjourned

Minutes Drafted by: FLAME TREE Freedom Center, Inc.	Date Submitted: 3/29/2025		
	D .		
Submitted by the GBEP Secretary:	Date:		
Approved by the GBEP with or without changes:	Date: 4/17/2025		
Certified by or Attested by the Chairperson:	Date: 4/14/2025		